Edwards Lifesciences’ (EW) Buy Rating Reiterated at BTIG Research

BTIG Research reaffirmed their buy rating on shares of Edwards Lifesciences (NYSE:EW) in a research note published on Wednesday morning,Benzinga reports. BTIG Research currently has a $103.00 price target on the medical research company’s stock.

EW has been the subject of several other research reports. Mizuho boosted their price objective on Edwards Lifesciences from $90.00 to $100.00 and gave the company an “outperform” rating in a report on Friday, October 31st. Raymond James Financial upgraded shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 price target for the company in a research note on Monday, November 3rd. Piper Sandler reaffirmed an “overweight” rating and issued a $100.00 price objective (up from $98.00) on shares of Edwards Lifesciences in a research note on Wednesday. Canaccord Genuity Group set a $87.00 target price on shares of Edwards Lifesciences and gave the stock a “hold” rating in a research report on Wednesday, December 17th. Finally, TD Cowen raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a research report on Friday, January 9th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $96.14.

Edwards Lifesciences Stock Down 0.8%

Shares of NYSE EW opened at $75.80 on Wednesday. The company has a quick ratio of 3.29, a current ratio of 4.00 and a debt-to-equity ratio of 0.06. The firm has a market cap of $43.99 billion, a PE ratio of 41.42, a P/E/G ratio of 2.00 and a beta of 0.94. The company’s fifty day simple moving average is $83.34 and its 200 day simple moving average is $81.08. Edwards Lifesciences has a 12-month low of $65.94 and a 12-month high of $87.89.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing the consensus estimate of $0.62 by ($0.04). The company had revenue of $1.57 billion for the quarter, compared to analyst estimates of $1.54 billion. Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. Edwards Lifesciences’s revenue for the quarter was up 13.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.59 EPS. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. As a group, sell-side analysts forecast that Edwards Lifesciences will post 2.45 earnings per share for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 7,700 shares of the stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $84.47, for a total transaction of $650,419.00. Following the completion of the transaction, the chief financial officer directly owned 39,898 shares of the company’s stock, valued at $3,370,184.06. This represents a 16.18% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Donald E. Bobo, Jr. sold 11,386 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $83.76, for a total transaction of $953,691.36. Following the completion of the sale, the vice president directly owned 38,970 shares in the company, valued at $3,264,127.20. This trade represents a 22.61% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 43,804 shares of company stock worth $3,699,082 over the last three months. 1.29% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of EW. Vanguard Group Inc. boosted its holdings in shares of Edwards Lifesciences by 0.5% in the third quarter. Vanguard Group Inc. now owns 70,363,210 shares of the medical research company’s stock worth $5,472,147,000 after acquiring an additional 365,581 shares during the period. State Street Corp lifted its holdings in Edwards Lifesciences by 1.5% during the 4th quarter. State Street Corp now owns 25,991,524 shares of the medical research company’s stock worth $2,215,777,000 after purchasing an additional 371,892 shares in the last quarter. Wellington Management Group LLP boosted its stake in Edwards Lifesciences by 4.9% in the 3rd quarter. Wellington Management Group LLP now owns 20,804,416 shares of the medical research company’s stock worth $1,617,959,000 after purchasing an additional 977,933 shares during the period. Bank of New York Mellon Corp grew its holdings in Edwards Lifesciences by 8.1% during the 3rd quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company’s stock valued at $1,478,425,000 after buying an additional 1,423,365 shares in the last quarter. Finally, Jennison Associates LLC increased its position in shares of Edwards Lifesciences by 19.6% during the third quarter. Jennison Associates LLC now owns 13,958,774 shares of the medical research company’s stock valued at $1,085,574,000 after buying an additional 2,287,783 shares during the period. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.